Head & Neck Cancers | Clinical

Evorpacept Pairs Well With Anticancer Regimens Plus Chemotherapy to Elicit Responses in Solid Tumors

November 10, 2021

The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.

FDA Grants Priority Review to Toripalimab +/- Chemotherapy in Advanced NPC

November 01, 2021

The biologics license application for toripalimab will undergo a speedy review by the FDA for consideration as a frontline treatment option for patients with advanced recurrent or metastatic nasopharyngeal carcinoma in combination with gemcitabine and cisplatin, and as a single-agent for the second-line or above treatment of recurrent or metastatic disease after platinum-containing chemotherapy.

Durvalumab/Metformin Combination May Be Effective in HNSCC

October 30, 2021

Joseph M. Curry, MD, discussed the efficacy of durvalumab in combination with metformin for the treatment of squamous cell carcinoma of the head and neck during an interview with Targeted Oncology.

NBTXR3 With or Without I/O Shows Survival Benefit in Locally Advanced HNSCC

October 28, 2021

NBTXR3, which is activated by radiotherapy, was found to be safe and tolerable in frail patients with head and neck squamous cell carcinoma. The agent can be used on its own or in combination with other immunotherapy agents.

Avasopasem Does Not Significantly Reduce Severe Oral Mucositis in Head and Neck Cancer

October 20, 2021

The primary end point of the ROMAN trial was not reached after avasopasem was found to not significantly reduce the incidence of severe oral mucositis. A full analysis of the results is ongoing.

HB-200 Vaccines Show Promised in HPV16+ Cancers

October 04, 2021

In an interview with Targeted Oncology, Marshall Posner, MD, discusses the use of the HB-201 and HB-202 vaccines in patients with human papillomavirus 16- positive cancers.

Larotrectinib Shows Significant Efficacy in NTRK+ Salivary Gland Tumors

September 26, 2021

Treatment with larotrectinib in patients with various subtypes of salivary gland tumors led to a high rate early and durable responses.

Neoadjuvant IO Response Suggestive of Long-Term Benefit in HPV– HNSCC

September 25, 2021

Responses achieved with immunotherapy preoperatively with could lead to lasting benefit in patients with HOV-associated head and neck squamous cell carcinoma.

Early-Phase Targeted Agents Are Poised to Expand Armamentarium in HNSCC

September 23, 2021

The emergence of early-phase immune-oncology agents and their respective novel mechanisms of action in head and neck squamous cell carcinoma suggests a new standard of care in the metastatic first-line setting within the next 2 years.

Iopofosine I-131 With EBRT Appears Safe in Head and Neck Cancer

September 22, 2021

Preliminary research suggests that lopofosine I-131 in combination with external beam radiation is safe and tolerable in patients with relapsed or refractory head and neck cancer.